Marketing Off-Label Uses to Physicians: FDA's Draft (Mis)Guidance

ISSN： 1536-0075

Source： American Journal of Bioethics, Vol.8, Iss.3, 2008-03, pp. : 1-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Researchers Have an Ethical Obligation to Disclose the Availability of Off-Label Marketed Drugs

By Silber Tomas J.

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 52-52

Routledge Ltd

Access to resources Recommend Favorite

The Relevance of Research Study Phase to Disclosure of Off-Label Drug Availability

By Baskaran Amrutha Sade Robert M.

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 53-54

Routledge Ltd

Access to resources Recommend Favorite

The Ethics of Disclosing to Research Subjects the Availability of Off-Label Marketed Drugs

By Taylor Holly A. Kuwana Ellen Wilfond Benjamin S.

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 51-51

Routledge Ltd

Access to resources Recommend Favorite

Cheap Trinkets, Effective Marketing: Small Gifts from Drug Companies to Physicians

By Brett Allan S.

American Journal of Bioethics, Vol. 3, Iss. 3, 2003-08 ,pp. : 52-54

Routledge Ltd

Access to resources Recommend Favorite

Professionalism: The Formation of Physicians

By Leach David C.

American Journal of Bioethics, Vol. 4, Iss. 2, 2004-06 ,pp. : 11-12

Routledge Ltd

Access to resources Recommend Favorite